CL2021000484A1 - Inhibición de la integrina a?ß6 - Google Patents
Inhibición de la integrina a?ß6Info
- Publication number
- CL2021000484A1 CL2021000484A1 CL2021000484A CL2021000484A CL2021000484A1 CL 2021000484 A1 CL2021000484 A1 CL 2021000484A1 CL 2021000484 A CL2021000484 A CL 2021000484A CL 2021000484 A CL2021000484 A CL 2021000484A CL 2021000484 A1 CL2021000484 A1 CL 2021000484A1
- Authority
- CL
- Chile
- Prior art keywords
- integrin
- compounds
- assay
- inhibition
- permeability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen inhibidores de molécula pequeña de la integrina a?ß6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina a?ß6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de a?ß6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724423P | 2018-08-29 | 2018-08-29 | |
US201962859457P | 2019-06-10 | 2019-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000484A1 true CL2021000484A1 (es) | 2021-09-03 |
Family
ID=67809398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000484A CL2021000484A1 (es) | 2018-08-29 | 2021-02-25 | Inhibición de la integrina a?ß6 |
Country Status (22)
Country | Link |
---|---|
US (4) | US20200071322A1 (es) |
EP (2) | EP3617206A1 (es) |
JP (1) | JP7540998B2 (es) |
KR (1) | KR20210065935A (es) |
CN (1) | CN112805001B (es) |
AU (1) | AU2019327475A1 (es) |
BR (1) | BR112021003859A2 (es) |
CA (1) | CA3109534A1 (es) |
CL (1) | CL2021000484A1 (es) |
CO (1) | CO2021002706A2 (es) |
CR (1) | CR20210109A (es) |
DO (1) | DOP2021000035A (es) |
EC (1) | ECSP21013620A (es) |
IL (1) | IL280782A (es) |
MA (1) | MA51066A (es) |
MX (1) | MX2021002181A (es) |
PE (1) | PE20211640A1 (es) |
PH (1) | PH12021550404A1 (es) |
SG (1) | SG11202101913PA (es) |
TW (1) | TW202035400A (es) |
UY (1) | UY38353A (es) |
WO (1) | WO2020047239A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
EP4328230A3 (en) | 2018-03-07 | 2024-04-24 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
JP7540998B2 (ja) | 2018-08-29 | 2024-08-27 | モーフィック セラピューティック,インコーポレイテッド | αvβ6インテグリンの阻害 |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
EP3873900A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
JP2023541427A (ja) * | 2020-09-11 | 2023-10-02 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 骨格筋送達プラットフォーム及び使用方法 |
CN116710169A (zh) | 2020-11-19 | 2023-09-05 | 普利安特治疗公司 | 整合素抑制剂及其用途 |
WO2024173570A1 (en) * | 2023-02-14 | 2024-08-22 | Morphic Therapeutic, Inc. | INHIBITING αvβ8 INTEGRIN |
WO2024173572A1 (en) * | 2023-02-14 | 2024-08-22 | Morphic Therapeutic, Inc. | INHIBITING α vβ8 INTEGRIN |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
TW221996B (es) | 1991-11-14 | 1994-04-01 | Glaxo Group Ltd | |
EP0623120A1 (en) | 1992-01-21 | 1994-11-09 | Glaxo Group Limited | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation |
ES2134870T3 (es) | 1993-05-01 | 1999-10-16 | Merck Patent Gmbh | Antagonistas del receptor de adhesion. |
US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
TR199801255T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r antagonistleri. |
US20010034445A1 (en) | 1995-12-29 | 2001-10-25 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
CN1209063A (zh) | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
CA2242877A1 (en) | 1996-01-16 | 1997-07-24 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE212990T1 (de) | 1996-03-20 | 2002-02-15 | Hoechst Ag | Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten |
UA49006C2 (uk) | 1996-03-29 | 2002-09-16 | Файзер Інк. | Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування |
WO1998008840A1 (en) | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
US5952341A (en) | 1996-10-30 | 1999-09-14 | Merck & Co., Inc. | Integrin antagonists |
JP2001503060A (ja) | 1996-10-30 | 2001-03-06 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
AU7105498A (en) | 1997-04-14 | 1998-11-11 | Merck & Co., Inc. | Combination therapy for the prevention and treatment of osteoporosis |
WO1999026945A1 (en) | 1997-11-26 | 1999-06-03 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
WO1999030713A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
TR200002557T2 (tr) | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | İntegrin reseptörü antagonistleri |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
DK1040111T3 (da) | 1997-12-17 | 2005-10-10 | Merck & Co Inc | Integrinreceptorantagonister |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO2000006169A1 (en) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
BR9916323A (pt) | 1998-12-19 | 2001-10-30 | Merck Patent Gmbh | Inibidores da integrina alfavbeta6 |
CA2358855A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
PT1187592E (pt) | 1999-06-02 | 2007-10-19 | Merck & Co Inc | Antagonistas dos receptores de integrina alfa v |
JP2003502373A (ja) | 1999-06-23 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
DE19933173A1 (de) | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001053297A1 (en) | 2000-01-20 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
AU780988B2 (en) | 2000-01-24 | 2005-04-28 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
US20040254211A1 (en) | 2000-09-14 | 2004-12-16 | Arison Byron H | Alpha v integrin receptor antagonists |
AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
AU2001295038A1 (en) | 2000-09-18 | 2002-03-26 | Merck & Co., Inc. | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist |
EP1425010B8 (en) | 2001-01-29 | 2012-03-28 | Janssen Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
JP2004528373A (ja) | 2001-05-03 | 2004-09-16 | メルク エンド カムパニー インコーポレーテッド | ベンズアゼピノンαVインテグリン受容体拮抗物質 |
US20040043988A1 (en) | 2001-06-15 | 2004-03-04 | Khanna Ish Kurmar | Cycloalkyl alkanoic acids as intergrin receptor antagonists |
DE10204789A1 (de) | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
DK1539739T3 (da) | 2002-08-16 | 2011-03-07 | Janssen Pharmaceutica Nv | Piperidinylforbindelser, der selektivt binder integriner |
FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物 |
CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
ES2428896T3 (es) | 2007-11-16 | 2013-11-12 | Ube Industries, Ltd. | Compuesto de benzacepinona |
US20120289481A1 (en) | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
KR20150038185A (ko) | 2012-07-18 | 2015-04-08 | 세인트 루이스 유니버시티 | 인테그린 길항제로서의 베타 아미노산 유도체 |
US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
WO2015103643A2 (en) | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
WO2015179823A2 (en) | 2014-05-23 | 2015-11-26 | The California Institute For Biomedical Research | Lung localized inhibitors of alpha(v)beta 6 |
WO2016022851A1 (en) | 2014-08-06 | 2016-02-11 | Children's Medical Center Corporation | Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN114805342A (zh) | 2015-02-19 | 2022-07-29 | 赛弗卢尔生命科学公司 | 氟化四氢萘啶基壬酸衍生物及其用途 |
ES2877707T3 (es) | 2015-03-25 | 2021-11-17 | Fujifilm Corp | Método para producir un nuevo compuesto que contiene nitrógeno o una sal del mismo, y producto intermedio de producción del mismo |
EP3288555A1 (en) | 2015-04-30 | 2018-03-07 | SciFluor Life Sciences, Inc. | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
BR112018012981A2 (pt) | 2015-12-30 | 2018-12-04 | Saint Louis University | derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas |
GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
GB201604680D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
PL3535397T3 (pl) | 2016-11-01 | 2022-03-07 | Arrowhead Pharmaceuticals, Inc. | Ligandy integryny alfa-v beta-6 i ich zastosowania |
WO2018085578A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin inhibitors in combination with an agent which interacts with a chemokine receptor |
WO2018085552A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
MX2019005306A (es) | 2016-11-08 | 2019-08-12 | Squibb Bristol Myers Co | Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. |
CA3042714A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Indazole derivatives as a .alpha.v integrin antagonists |
ES2898835T3 (es) | 2016-11-08 | 2022-03-09 | Bristol Myers Squibb Co | Azol amidas y aminas como inhibidores de la integrina alfav |
CN110167935B (zh) | 2016-11-08 | 2022-05-27 | 百时美施贵宝公司 | 作为αV整合素抑制剂的3-经取代的丙酸 |
PL3538528T3 (pl) | 2016-11-08 | 2021-05-31 | Bristol-Myers Squibb Company | Amidy pirolu jako inhibitory integryny alfa v |
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
US11306084B2 (en) | 2016-12-29 | 2022-04-19 | Saint Louis University | Integrin antagonists |
CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
MA47697A (fr) * | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
EP4328230A3 (en) | 2018-03-07 | 2024-04-24 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
US20210284638A1 (en) | 2018-07-03 | 2021-09-16 | Saint Louis University | ALPHAvBETA1 INTEGRIN ANTAGONISTS |
JP7540998B2 (ja) | 2018-08-29 | 2024-08-27 | モーフィック セラピューティック,インコーポレイテッド | αvβ6インテグリンの阻害 |
WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
EP3844162A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF AV-BETA6 INTEGRIN |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
WO2020210404A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
-
2019
- 2019-08-29 JP JP2021510691A patent/JP7540998B2/ja active Active
- 2019-08-29 UY UY0001038353A patent/UY38353A/es not_active Application Discontinuation
- 2019-08-29 BR BR112021003859-0A patent/BR112021003859A2/pt unknown
- 2019-08-29 SG SG11202101913PA patent/SG11202101913PA/en unknown
- 2019-08-29 KR KR1020217006113A patent/KR20210065935A/ko not_active Application Discontinuation
- 2019-08-29 US US16/555,589 patent/US20200071322A1/en not_active Abandoned
- 2019-08-29 CA CA3109534A patent/CA3109534A1/en active Pending
- 2019-08-29 MA MA051066A patent/MA51066A/fr unknown
- 2019-08-29 CN CN201980056588.3A patent/CN112805001B/zh active Active
- 2019-08-29 TW TW108131114A patent/TW202035400A/zh unknown
- 2019-08-29 PE PE2021000252A patent/PE20211640A1/es unknown
- 2019-08-29 MX MX2021002181A patent/MX2021002181A/es unknown
- 2019-08-29 CR CR20210109A patent/CR20210109A/es unknown
- 2019-08-29 AU AU2019327475A patent/AU2019327475A1/en active Pending
- 2019-08-29 EP EP19194490.9A patent/EP3617206A1/en not_active Withdrawn
- 2019-08-29 WO PCT/US2019/048782 patent/WO2020047239A1/en active Application Filing
- 2019-08-29 EP EP22173105.2A patent/EP4086254A1/en active Pending
-
2020
- 2020-07-27 US US16/939,848 patent/US20200354359A1/en not_active Abandoned
- 2020-08-24 US US17/001,086 patent/US11021480B2/en active Active
-
2021
- 2021-02-10 IL IL280782A patent/IL280782A/en unknown
- 2021-02-25 CL CL2021000484A patent/CL2021000484A1/es unknown
- 2021-02-25 DO DO2021000035A patent/DOP2021000035A/es unknown
- 2021-02-26 PH PH12021550404A patent/PH12021550404A1/en unknown
- 2021-02-26 EC ECSENADI202113620A patent/ECSP21013620A/es unknown
- 2021-02-26 CO CONC2021/0002706A patent/CO2021002706A2/es unknown
- 2021-04-23 US US17/239,045 patent/US11739087B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2020047239A1 (en) | 2020-03-05 |
US20200385384A1 (en) | 2020-12-10 |
US11739087B2 (en) | 2023-08-29 |
US11021480B2 (en) | 2021-06-01 |
MA51066A (fr) | 2020-10-14 |
US20220073511A1 (en) | 2022-03-10 |
TW202035400A (zh) | 2020-10-01 |
JP7540998B2 (ja) | 2024-08-27 |
EP4086254A1 (en) | 2022-11-09 |
CR20210109A (es) | 2021-06-24 |
EP3617206A1 (en) | 2020-03-04 |
US20200071322A1 (en) | 2020-03-05 |
UY38353A (es) | 2020-03-31 |
AU2019327475A1 (en) | 2021-03-11 |
SG11202101913PA (en) | 2021-03-30 |
JP2021535141A (ja) | 2021-12-16 |
CO2021002706A2 (es) | 2021-05-20 |
IL280782A (en) | 2021-04-29 |
PE20211640A1 (es) | 2021-08-24 |
BR112021003859A2 (pt) | 2021-05-18 |
DOP2021000035A (es) | 2021-06-30 |
PH12021550404A1 (en) | 2021-10-04 |
CN112805001B (zh) | 2024-07-23 |
CA3109534A1 (en) | 2020-03-05 |
ECSP21013620A (es) | 2021-05-31 |
MX2021002181A (es) | 2021-07-15 |
US20200354359A1 (en) | 2020-11-12 |
CN112805001A (zh) | 2021-05-14 |
KR20210065935A (ko) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000484A1 (es) | Inhibición de la integrina a?ß6 | |
CU24387B1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
ECSP11010889A (es) | INHIBIDORES DE cMET | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
CR11492A (es) | Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i | |
UY31261A1 (es) | Imidazopiridinonas, composiciones que las contienen, procedimientos para su preparacion, intermedios utilizados en tales procedimientos y aplicaciones. | |
UY29479A1 (es) | Inhibidores de adn-pk | |
CU23778B7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
DOP2010000191A (es) | Derivados bis-(sulfonilamino) | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
ECSP078055A (es) | Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas | |
UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
UY31479A1 (es) | 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
BRPI0519710A2 (pt) | aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
CL2019001804A1 (es) | Activador de nrf2. | |
UY30488A1 (es) | Bencilaminas,un proceso para su produccion y su uso como agentes anti-inflamatorios. | |
MX2020004554A (es) | Ligandos de integrina y usos de estos. | |
CR20110630A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
CL2008001691A1 (es) | Compuestos derivados de oxazolidinosas sustituidas con actividad inhibidora de trombina como factor xa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades trombo embolicas, hipertonia pulmonar, sepsis, entre otras. |